Table 2.
Median rate (per 100 patient years of follow-up) of selected efficacy and safety outcomes and probability that each stent type has lowest event rate, from mixed treatment comparison analysis of all available trials in network
| Stent type | TVR rate (95% CrI) | Probability best (%) | Death rate (95% CrI) | Probability best (%) | MI rate (95% CrI) | Probability best (%) | ARC definite ST (95% CrI) | Probability best (%) |
|---|---|---|---|---|---|---|---|---|
| Bare metal | 8.06 (7.41 to 8.69) | 0 | 2.11 (1.79 to 2. 54) | 0 | 1.88 (1.54 to 2.30) | 0 | 0.39 (0.25 to 0.60) | 0 |
| Sirolimus | 3.61 (32.25 to 40.03) | 0 | 1.82 (1.51 to 2.19) | 0 | 1.56 (1.26 to 1.92) | 0 | 0.39 (0.25 to 0.62) | 0 |
| Paclitaxel | 4.97 (4.41 to 5.57) | 0 | 1.87 (1.52 to 2.27) | 0 | 1.84 (1.48 to 2.26) | 0 | 0.46 (0.29 to 0.75) | 0 |
| CoCr-everolimus | 3.21 (2.73 to 3.68) | 9 | 1.52 (1.20 to 1.91) | 18 | 1.22 (0.96 to 1.55) | 29 | 0.13 (0.07 to 0.24) | 81 |
| PtCr-everolimus | 2.95 (2.06 to 4.17) | 50 | 1.51 (0.99 to 2.30) | 31 | 1.15 (0.79 to 1.72) | 56 | 0.19 (0.07 to 0.50) | 17 |
| Zotarolimus-E | 4.75 (4.07 to 5.63) | 0 | 1.84 (1.37 to 2.45) | 2 | 1.52 (1.18 to 1.94) | 0 | 0.30 (0.17 to 0.57) | 0 |
| Zotarolimus-R | 3.08 (2.26 to 3.98) | 30 | 1.46 (0.97 to 2.26) | 40 | 1.34 (0.98 to 1.86) | 12 | 0.34 (0.13 to 0.82) | 0 |
| Biodegradable polymer | 3.30 (2.79 to 3.87) | 9 | 1.70 (1.31 to 2.21) | 6 | 1.51 (1.16 to 1.93) | 0 | 0.28 (0.16 to 0.48) | 0 |
Rates are per 100 patient years of follow-up using Bayesian Markov Chain Monte Carlo (MCMC) method.
ARC=Academic Research Consortium; CoCr=cobalt chromium; CrI=credibility interval; MI=myocardial infarction; PtCr=platinum chromium; ST=stent thrombosis; TVR=target vessel revascularization.